- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00363090
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from growing. Giving alemtuzumab together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed aggressive stage II, stage III, or stage IV T-cell non-Hodgkin's lymphoma.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
OBJECTIVES:
Primary
- Establish the safety and dose-limiting toxicities of alemtuzumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) chemotherapy in patients with newly diagnosed, stage II-IV aggressive peripheral T-cell non-Hodgkin's lymphoma.
- Measure the pharmacokinetics of alemtuzumab using different subcutaneous doses and schedules to determine the dose with the highest achievable drug levels with acceptable toxicities worthy of further investigation.
Secondary
- Determine the efficacy of alemtuzumab in combination with CHOP chemotherapy using escalating doses and 2 different drug schedules, as defined by overall response rate, progression-free survival, and overall survival.
- Measure the effects of this regimen on T-cell reconstitution and cytomegalovirus reactivation.
OUTLINE: This is a multicenter, phase I, dose-escalation study of alemtuzumab followed by an open-label, phase II study.
- Phase I: Patients receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Patients also receive alemtuzumab subcutaneously (SC) on day 1 OR on days 1, 8, and 15. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of alemtuzumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Phase II: Patients receive CHOP chemotherapy and alemtuzumab (at the MTD determined in phase I) as in phase I (on the most effective regimen).
Patients undergo blood collection at baseline, periodically during study treatment, and after completion of study treatment for pharmacokinetics and other correlative studies. Samples are examined for presence of cytomegalovirus antigen and by flow cytometry for B- and T-cell quantification.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 84 patients will be accrued for this study.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- Reclutamento
- St. Paul's Hospital at Providence Health Care - Vancouver
-
Contatto:
- Contact Person
- Numero di telefono: 604-806-9656
-
-
Ontario
-
Hamilton, Ontario, Canada, N6A 4L6
- Reclutamento
- Margaret and Charles Juravinski Cancer Centre
-
Contatto:
- Graeme Fraser, MD, FRCPC
- Numero di telefono: 905-575-7820
-
London, Ontario, Canada, N6A 4L6
- Reclutamento
- London Regional Cancer Program at London Health Sciences Centre
-
Contatto:
- Joy Mangel, MD
- Numero di telefono: 519-685-8615
- Email: joy.mangel@lhsc.on.ca
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- Princess Margaret Hospital
-
Contatto:
- Michael R. Crump, MD, FRCPC
- Numero di telefono: 416-946-4567
- Email: michael.crump@uhn.on.ca
-
Toronto, Ontario, Canada, M4N 3M5
- Reclutamento
- Odette Cancer Centre at Sunnybrook
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Histologically confirmed aggressive peripheral T-cell non-Hodgkin's lymphoma (NHL), including the following nodal or extranodal subtypes:
Nodal:
- Angioimmunoblastic lymphadenopathy
- ALK 1-negative anaplastic large cell NHL
- Peripheral T-cell lymphoma not otherwise specified
Extranodal:
- Hepatosplenic NHL
- Enteropathy-associated NHL
- Panniculitic NHL
- Stage II-IV disease
- Newly diagnosed, CD52+ disease
- Measurable or evaluable disease
- No known CNS involvement with lymphoma
- No nasal natural killer T-cell NHL
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy > 4 months
- Absolute neutrophil count ≥ 1,000/mm³*
- Platelet count ≥ 75,000/mm³*
- Hemoglobin ≥ 8.5 g/dL*
- Bilirubin < 2.0 mg/dL
- Alkaline phosphatase ≤ 2 times upper limit of normal (ULN)
- AST or ALT < 2 times ULN
- Creatinine < 1.5 mg/dL*
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No known hypersensitivity to any of the study drugs
- No serious illnesses that would preclude compliance with study requirements
- No known HIV positivity
- No other preexisting immunodeficiency (e.g., post-organ transplant)
- No other malignancy within the past 5 years except cervical carcinoma in situ or nonmelanoma skin cancer NOTE: *Unless directly attributable to NHL
PRIOR CONCURRENT THERAPY:
No prior chemotherapy or radiotherapy
- Up to 7 days of prednisone preceding initiation of chemotherapy allowed
- No other concurrent chemotherapy, radiotherapy, or immunotherapy
- No other concurrent corticosteroids except dexamethasone used as an antiemetic for a brief period
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Mascheramento: Nessuno (etichetta aperta)
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
---|
Sicurezza
|
Tossicità dose-limitanti
|
Toxicity as assessed by NCI Common Toxicity Criteria Version 3.0
|
Pharmacokinetics of alemtuzumab
|
Misure di risultato secondarie
Misura del risultato |
---|
Sopravvivenza libera da progressione
|
Sopravvivenza globale
|
Tasso di risposta complessivo
|
Efficacy as assessed by clinical, radiologic, pathologic, and laboratory measurements
|
Effects of treatment on T- and B-cell reconstitution by flow cytometry at baseline and at 3, 6, and 12 months
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Rena Buckstein, MD, Toronto Sunnybrook Regional Cancer Centre
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- linfoma diffuso a grandi cellule dell'adulto in stadio III
- linfoma diffuso a grandi cellule dell'adulto in stadio IV
- linfoma diffuso a cellule miste in stadio III dell'adulto
- linfoma diffuso a cellule miste adulto stadio IV
- leucemia/linfoma a cellule T dell'adulto in stadio III
- leucemia/linfoma a cellule T dell'adulto in stadio IV
- linfoma angioimmunoblastico a cellule T
- linfoma anaplastico a grandi cellule
- linfoma diffuso a grandi cellule dell'adulto di stadio II non contiguo
- linfoma diffuso a cellule miste dell'adulto di stadio II non contiguo
- linfoma diffuso a grandi cellule dell'adulto di stadio II contiguo
- linfoma diffuso a cellule miste adulto stadio II contiguo
- leucemia/linfoma a cellule T dell'adulto di stadio II
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie
- Malattie linfoproliferative
- Malattie linfatiche
- Disturbi immunoproliferativi
- Linfoma
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antinfiammatori
- Agenti antireumatici
- Agenti antineoplastici
- Agenti immunosoppressivi
- Fattori immunologici
- Modulatori della tubulina
- Agenti antimitotici
- Modulatori della mitosi
- Glucocorticoidi
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Agenti antineoplastici, ormonali
- Agenti Antineoplastici, Alchilanti
- Agenti Alchilanti
- Agonisti mieloablativi
- Agenti antineoplastici, fitogenici
- Inibitori della topoisomerasi II
- Inibitori della topoisomerasi
- Agenti antineoplastici, immunologici
- Antibiotici, Antineoplastici
- Ciclofosfamide
- Prednisone
- Doxorubicina
- Doxorubicina liposomiale
- Vincristina
- Alemtuzumab
Altri numeri di identificazione dello studio
- CDR0000491451
- TSRCC-164-2006
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .